Publication:
Hepatitis E Virus Infection in Turkey: A Systematic Review

dc.authorscopusid24073322700
dc.authorscopusid7006484311
dc.contributor.authorLeblebicioglu, H.
dc.contributor.authorÖzaras, R.
dc.date.accessioned2020-06-21T13:11:10Z
dc.date.available2020-06-21T13:11:10Z
dc.date.issued2018
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Leblebicioglu] Hakan, Department of Infectious Diseases and Clinical Microbiology, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Özaras] Reŝat, Medilife Hospital, Istanbul, Istanbul, Turkeyen_US
dc.description.abstractHepatitis E virus (HEV), a non-enveloped single stranded RNA virus causes sporadic cases of hepatitis or outbreaks. The disease is generally self-limited although it may cause fulminant hepatitis in pregnant women, elderly, those with underlying chronic hepatitis, immunosuppressed, and transplant recipients. It is transmitted through fecal-oral route and zoonotic transmission. Hepatitis is a main health care problem in Turkey; HBV and HCV prevalences are 4 and 1% respectively. Hepatitis D represents another considerable hepatitis etiology with a prevalence of 5-27%. The information about HEV is not clear. In this systematic review, we aimed to analyze HEV studies reported from Turkey, to determine the current situation of the disease in the country, to delineate the limits of the studies and to determine the future study areas. The prevalence of HEV ranged from 0 to 12.4%. Children had lower prevalence than the adults. The prevalence was determined as 7-8% in pregnant women, 13% in chronic HBV patients, 54% in chronic HCV patients, 13.9-20.6% in patients with chronic renal failure, and ≈35% in agriculture workers. Among individuals immigrating form Turkey to Europe, HEV seroprevalence was found 10.3% in Italy and 33.4% in the Netherlands. HEV prevalence seems high in certain risk groups. Although previous studies suggest that Turkey is among the endemic countries of HEV, there are some pitfalls for the analysis of data: the studies are not powered enough to represent the whole population; they did not include immunosuppressed patients and solid organ recipients; and the prevalence of non-A non-B hepatitis was not determined. © 2018 The Author(s).en_US
dc.identifier.doi10.1186/s12941-018-0269-6
dc.identifier.issn1476-0711
dc.identifier.issue1en_US
dc.identifier.pmid29716597
dc.identifier.scopus2-s2.0-85046297194
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1186/s12941-018-0269-6
dc.identifier.volume17en_US
dc.identifier.wosWOS:000431384500001
dc.identifier.wosqualityQ2
dc.language.isoenen_US
dc.publisherBioMed Central Ltd. info@biomedcentral.comen_US
dc.relation.ispartofAnnals of Clinical Microbiology and Antimicrobialsen_US
dc.relation.journalAnnals of Clinical Microbiology and Antimicrobialsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHepatitis E Virusen_US
dc.subjectPrevalenceen_US
dc.subjectSystematic Reviewen_US
dc.subjectTravelen_US
dc.subjectTurkeyen_US
dc.titleHepatitis E Virus Infection in Turkey: A Systematic Reviewen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files